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Abstract
Histone deacetylase (HDAC) 4 is a transcriptional repressor that contains a glutamine-rich domain. We hypothesised that it
may be involved in the molecular pathogenesis of Huntington’s disease (HD), a protein-folding neurodegenerative disorder
caused by an aggregation-prone polyglutamine expansion in the huntingtin protein. We found that HDAC4 associates with
huntingtin in a polyglutamine-length-dependent manner and co-localises with cytoplasmic inclusions. We show that
HDAC4 reduction delayed cytoplasmic aggregate formation, restored Bdnf transcript levels, and rescued neuronal and
cortico-striatal synaptic function in HD mouse models. This was accompanied by an improvement in motor coordination,
neurological phenotypes, and increased lifespan. Surprisingly, HDAC4 reduction had no effect on global transcriptional
dysfunction and did not modulate nuclear huntingtin aggregation. Our results define a crucial role for the cytoplasmic
aggregation process in the molecular pathology of HD. HDAC4 reduction presents a novel strategy for targeting huntingtin
aggregation, which may be amenable to small-molecule therapeutics.
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Introduction
Huntington’s disease (HD) is a progressive, inherited neurolog-
ical disorder characterized by severe motor, cognitive, behaviour-
al, and physiological dysfunction for which there is no effective
disease-modifying treatment [1]. The disease is caused by the
expansion of a CAG repeat to more than 35 CAGs within exon 1
of the HTT gene. At the molecular level, mutant huntingtin (HTT)
containing an expanded polyQ stretch has a propensity to self-
aggregate to produce a wide-range of oligomeric species and
insoluble aggregates and exerts a gain of toxic function through
aberrant protein–protein interactions [2]. Therefore, as with other
neurodegenerative diseases such as Alzheimer’s disease, Parkin-
son’s disease, and the prion diseases, the polyglutamine (polyQ)
disorders including HD are associated with the accumulation of
misfolded proteins leading to neuronal dysfunction and cell death.
Transcriptional dysregulation is part of the complex molecular
pathogenesis of HD, to which abnormal histone acetylation and
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chromatin remodelling may contribute [3]. The imbalance in
histone acetylation was proposed to be caused by the inactivation
of histone acetyltransferases, which led to the pursuit of histone
deacetylases (HDACs) as HD therepeutic targets [4,5]. There are
11 mammalian Zn2+-dependent HDACs divided into three groups
based on structural and functional similarities: class I (HDACs: 1,
2, 3, 8), class IIa (HDACs: 4, 5, 7, 9), class IIb (HDACs: 6, 10), and
HDAC11 as class IV [6]. Initial genetic and pharmacological
studies performed in flies, worms, and HD mouse models have
suggested that HDAC inhibitors may have a significant therapeu-
tic potential [4,5].
The preclinical evaluation of the HDAC inhibitor suberoylani-
lide hydroxamic acid (SAHA) demonstrated a dramatic improve-
ment in the motor impairment that develops in the R6/2 HD
mouse model [7]. Initially, SAHA was shown to inhibit class I and
II HDACs at nanomolar concentrations, although it is predom-
inantly a class I inhibitor [8]. More recently, SAHA was shown to
lead to the degradation of HDACs 4 and 5 via RANBP2-mediated
proteasome degradation in cancer cell lines [9]. Following on from
this, we demonstrated that in addition to its deacetylase activity
and the known effect on decreasing Hdac7 mRNA levels [10],
SAHA treatment results in a reduction in HDAC2 and HDAC4 in
brain regions of both WT and R6/2 mice, without affecting their
transcript levels in vivo. This was associated with a reduction in
aggregate load and the restoration of cortical Bdnf transcript levels
in R6/2 mice [11].
It is well-established that HDAC4 acts as a transcriptional
repressor that shuttles between the nucleus and cytoplasm.
Phosphorylated HDAC4 is retained in the cytoplasm through its
association with 14-3-3 proteins [12]. The N-terminal region of
HDAC4 contains a MEF2 binding site and represses the
transcription of MEF2-dependent genes important in the regula-
tion of neuronal cell death [13]. In this context, MEF2 can act as a
neuronal survival factor, and its inhibition has been linked to the
death of neurons in several cell culture systems [14]. Crystalliza-
tion of the N-terminal domain of HDAC4 suggested that HDAC4
might have the propensity to self-aggregate through its glutamine-
rich domains, consistent with cell-culture studies [15]. Interesting-
ly, regions containing high glutamine content in proteins have
been observed to facilitate interactions with other glutamine-rich
proteins, leading to the spontaneous assembly of insoluble toxic
amyloid-like structures in mammalian cells [16].
In this study, we identified a novel mechanism by which
HDACs can modify HD pathogenesis in vivo and found that
HDAC4 reduction delays the HTT aggregation process. We
demonstrated that HDAC4 associates with mutant exon 1 and
full-length HTT in vivo in a polyQ-length-dependent manner and
co-localizes with cytoplasmic inclusions in the brains of HD mouse
models. HDAC4 knock-down inhibited aggregate formation in
both the R6/2 (N-terminal fragment) and HdhQ150 (full-length
knock-in) HD mouse models. This delay in aggregation occurred
in the cytoplasm, consistent with the subcellular localisation of
HDAC4 in mouse brain. We found no evidence for HDAC4
translocation to the nucleus during disease progression, and
HDAC4 knock-down had no effect on HTT aggregation in the
nucleus and no impact on global transcriptional dysregulation.
HDAC4 reduction led to a marked restoration of the membrane
properties of medium spiny neurons (MSNs) and of corticostriatal
synaptic transmission. This was associated with an improvement in
neurological phenotypes and extended survival. These data
provide a clear demonstration that cytoplasmic pathogenic
mechanisms contribute to HD-related neurodegenerative pheno-
types and identify HDAC4 as a therapeutic target for HD.
Results
Molecular Characterisation of Hdac4 Knock-Down in
Mouse Models of HD
In order to investigate whether HDAC4 is involved in the
molecular pathogenesis of HD, we used a genetic approach to
reduce HDAC4 levels in both the R6/2 and HdhQ150 knock-in
HD mouse models. R6/2 mice are transgenic for a mutated N-
terminal exon 1 HTT fragment [17]. The HdhQ150 mice have an
expanded CAG repeat knocked in to the mouse huntingtin gene
(Htt) [18,19], which is partially mis-spliced with the result that
these mice express mutant versions of both an exon 1 HTT and a
full-length HTT protein [20]. Because Hdac4 knock-out
(Hdac4KO) mice die in early postnatal life [21], the HD mutation
could not be transferred onto an Hdac4 null background.
Therefore, we crossed males for each of the HD mouse models
to Hdac4HET females (Figure 1A). Analysis of the progeny
indicated that Hdac4 mRNA levels were decreased to approxi-
mately 50% in both Hdac4HET and double-mutant mice in both
crosses (Figure 1B).
Since HDAC4 functions as a transcriptional corepressor [22], it
was important to check whether Hdac4 knock-down regulated the
expression of the R6/2 transgene, as this would be expected to
modulate the onset and progression of disease in R6/2 mice.
Therefore, we used Taqman qPCR to demonstrate that exon 1
HTT mRNA was not altered in the cortex (Figure 1C),
cerebellum, nor striatum (Figure S1A) of Dble::R6/2 mice.
Similarly, we showed that endogenous Htt levels were unchanged
as a consequence of HDAC4 reduction in both R6/2 and
HdhQ150 mice (Figures 1D and S1B). In addition, given that CAG
repeat length is linked to aggregation kinetics and disease
Author Summary
Huntington’s disease (HD) is a late-onset neurodegenera-
tive disorder caused by protein-folding defects in the
huntingtin protein. Mutations in huntingtin can result in
extra-long tracts of the amino acid glutamine, resulting in
aberrant interactions with other proteins and also causing
huntingtin proteins to self-associate and -aggregate. The
pathology of HD is therefore associated with nuclear and
cytoplasmic aggregates. HDAC4 is a histone deacetylase
protein traditionally associated with roles in transcription
repression. The HDAC4 protein contains a glutamine-rich
domain and in this work we find that HDAC4 associates
with huntingtin in a polyglutamine-length-dependent
manner and that these proteins co-localise in cytoplasmic
inclusions. Importantly, reducing HDAC4 levels delays
cytoplasmic aggregate formation and rescues neuronal
and cortico-striatal synaptic function in mouse models of
HD. In addition, we observe improvements in motor
coordination and neurological phenotypes, as well as
increased lifespan in these mice. Nuclear huntingin
aggregates or transcription regulation, however, remained
unaffected when HDAC4 levels were reduced to enable
these effects. Our results thus provide valuable insight into
separating cytoplasmic and nuclear pathologies, and
define a crucial role for cytoplasmic aggregations in HD
progression. HDAC4 reduction presents a novel strategy
for alleviating the toxicity of huntingtin protein aggrega-
tion, thereby influencing the molecular pathology of
Huntington’s disease. As there are currently no disease-
modifying therapeutics available for Huntington’s disease,
we hope that this HDAC4-mediated regulation may be
amenable to small-molecule therapeutics.
HDAC4: A Novel Therapeutic Target for HD
PLOS Biology | www.plosbiology.org 2 November 2013 | Volume 11 | Issue 11 | e1001717
progression, we ensured that the CAG repeats were maintained at
comparable levels throughout the course of this study (Table S1).
Alteration of HDAC4 levels has been shown to modulate Hdac9
in muscle cells [23] and Hdac5 in primary mouse hepatocytes [24].
Therefore, we used Taqman qPCR to show that Hdac4 knock-
down did not affect the levels of the other 10 Hdacs in brain regions
of mice that did or did not express the HD mutation (Figures 1E
and S1C and S1D).
HDAC4 Knock-Down Reduces Aggregate Load and
Increases Levels of Soluble HTT in Mouse Models of HD
Bioinformatic predictions of HDAC4 structure suggested that
HDAC4 has an N-terminal coil–coil domain within which it
possesses short polyQ tracts that might convey an increased
propensity for amyloid formation [15] as was confirmed in
cultured cells [13]. Hence, we hypothesized that HDAC4 might
exhibit pro-aggregation properties in HD mouse models. In order
Figure 1. Hdac4 reduction does not alter the expression levels of HTT exon 1, endogenous Htt, or other Hdacs. (A) Breeding scheme
used to reduce Hdac4 levels in both R6/2 and heterozygous HdhQ150 mice. WT, wild type; Hdac4HET, Hdac4KO heterozygotes; Dble::R6/2, R6/2 mice
heterozygous for Hdac4KO; Dble::HdhQ150, HdhQ150 mice heterozygous for Hdac4KO. (B) Hdac4 transcript levels were decreased in Hdac4HET,
Dble::R6/2, and Dble::HdhQ150 mice as measured by Taqman qPCR. (C) Taqman qPCR showed that HTT exon 1 transgene levels did not differ
between R6/2 and Dble::R6/2 mice. (D) Taqman qPCR showed that the expression of endogenous Htt was equivalent between WT and Hdac4HETs
and did not change when Hdac4 was knocked down in R6/2 or HdhQ150 mice. (E) The transcript levels of other Hdacs were equivalent to WT levels in
Hdac4HET, R6/2, and Dble::R6/2 mice as determined by Taqman qPCR. All Taqman qPCR values were normalized to the geometric mean of three
housekeeping genes: Atp5b, Canx, and Rpl13a. Error bars are SEM using Student’s t test (n= 8). **p,0.01; ***p,0.001.
doi:10.1371/journal.pbio.1001717.g001
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to investigate the molecular consequences of HDAC4 knock-down
in HD mice, we employed the Seprion ligand ELISA to quantify
aggregate load [25] and time-resolved Fo¨rster resonance energy
transfer (TR-FRET) to measure soluble mutant HTT levels [26].
TR-FRET detects a FRET signal between two appropriately
labelled antibodies. In this case, 2B7 (epitope: 1–17 amino acids of
HTT) is paired with MW1 (epitope: polyQ in nonaggregated
HTT).
In R6/2 mice, the level of soluble exon 1 HTT decreases with
disease progression as a consequence of its aggregation. The
Seprion ELISA revealed that HDAC4 knock-down reduced the
aggregate load in the cortex (Figure 2A), brain stem, hippocampus,
and cerebellum (Figure S2A) of Dble::R6/2 mice at 4 and 9 wk
but that this effect had diminished by 15 wk of age. Accordingly,
TR-FRET demonstrated that reduced HDAC4 levels led to an
increase in soluble exon 1 HTT in the cortex (Figure 2B), brain
stem, hippocampus, and cerebellum (Figure S2B) of Dble::R6/2
mice at 4 and 9 but not at 15 wk of age. This shift in the ratio
between soluble and aggregated exon 1 HTT levels can be
visualised on the western blots in Figure 2D. We performed
Seprion ELISA to determine whether similar results could be
obtained in the HdhQ150 knock-in mice. A significant reduction in
the aggregate load was observed in the striatum, cortex and
cerebellum of Dble::HdhQ150 mice at 6 and 10 mo of age
(Figure 2C). Taken together, these data show that HDAC4 knock-
down significantly reduced aggregate load and increased levels of
soluble mutant HTT in HD mouse models, reflecting a delay in
the aggregation process.
We used Hdac4KO P3 brain tissue to confirm that the
commercially available antibodies Sigma (DM-15), Santa Cruz
(H-92), and Cell Signalling (CS2072) detected an HDAC4 specific
signal (Figure S2C and unpublished data). On western blotting of
nuclear and cytoplasmic fractions of mouse brain, we found that
only trace amounts of HDAC4 could be detected in the nuclear
fraction (Figure 2E). Therefore, to investigate whether the
reduction in aggregation occurred in the cytoplasm, as would be
consistent with the presence of HDAC4, we perfomed cellular
fractionation on 4 wk and 9 wk brain tissue. We then resolved
detergent insoluble high-molecular weight aggregates from the
nuclear and cytoplasmic lysates by agarose gel electrophoresis
(AGERA), prepared western blots, and performed immunodetec-
tion with the S830 antibody (epitope: exon 1 HTT). We found that
HDAC4 knock-down reduced the aggregate load in the cytoplasm
but not in the nucleus of Dble::R6/2 mice at both 4 (Figure S2D)
and 9 (Figure 2F) wk of age. Consistent with this, we found that the
cytoplasmic steady-state levels of HDAC4 were significantly
reduced in Dble::R6/2 mice as compared to R6/2 at both 4
(Figure S2E) and 9 (Figure 2G) wk of age. The purity of the
cellular fractions was validated by immunoblotting with a-tubulin
and histone H3 antibodies (Figures 2F and S2D).
The Decrease in Aggregate Load Is Not a Consequence of
Strain Background
The R6/2 colony was maintained by backrossing to (CBA/
Ca6C57BL/6J)F1 mice and the Hdac4 knock-out mice had been
bred to the same F1 background for more than six generations.
We know from having bred R6/2 mice for 99 generations and
from multiple experiments that the differential segregation of
CBA/Ca and C57BL/6J alleles has no effect on HD-related
phenotypes in R6/2 mice [10,27–33]. However, the Hdac4 null
allele had been created on a 129S mouse strain background, and it
is inevitable that even after backcrossing to (CBA/Ca6C57BL/
6J)F1 mice for multiple generations, the Hdac4 null allele would be
retained in a genomic region of 129S DNA that had not been
removed by recombination. Therefore, it was possible that the
observed effects might be due to genetic variation in the 129S
Hdac4-linked haplotype rather than through a reduction in
HDAC4. To rule out this scenario, we identified an Hdac4-linked
single nucleotide polymorphism (SNP) that was polymorphic
between 129S and both the C57BL/6J and CBA/Ca strain
backgrounds. We crossed R6/2 mice to (129S6C57BL/6J)F1s
and identified R6/2 progeny that either did not carry or were
heterozygous for the 129S SNP (n=7/genotype). The heterozy-
gous mice contained the 129S haplotype with a wild-type Hdac4
allele. Seprion ELISA on 9-wk-old cortex showed that the 129S
Hdac4-linked haplotype did not modify aggregate load in R6/2
mice (Figure S2F), confirming the role for HDAC4 in aggregate
reduction.
HDAC4 Associates with Mutant HTT and Colocalizes with
Cytoplasmic Inclusions
To further understand the nature of the reduction in aggregate
load by HDAC4 knock-down, we reasoned that HDAC4 might
associate with HTT. Hence, we employed an in vitro GST pull-
down assay and found that HDAC4 interacted specifically with
exon 1 HTT containing a 53 polyQ tract but not with its 20
polyQ counterpart (Figure 3A). To determine whether HDAC4
associates with endogenous HTT, we immunoprecipitated HTT
(2B7, epitope 1–17) or HDAC4 (DM-15) from brain lysates of 8-
wk-old WT (7Q), HdhQ150 heterozygous, and HdhQ150
homozygous mice and immunoblotted with the MW1 (soluble
mutant HTT), MAB2166 (soluble wild type and mutant HTT),
and H-92 (HDAC4) antibodies. We found that mutant but not
wild-type HTT co-immunoprecipitated with HDAC4 (Figure 3B).
To investigate the effect of polyQ length on this interaction, we
repeated the experiment with lysates from 8-wk-old heterozygous
knock-in mice carrying polyQ tracts of 20 (HdhQ20) or 80
(HdhQ80). We found that HDAC4 could immunoprecipitate
HTT containing 80 but not 20 glutamines (Figure 3C), consistent
with the in vitro pull-down data. The sequence of HDAC4 is very
similar to the class IIa member HDAC5. Therefore, to
investigate the specificity of these interactions, we repeated the
in vitro and in vivo immunprecipitations with an antibody specific
to HDAC5. Although there was a weak interaction between exon
1 HTT and HDAC5 by in vitro pull-down (Figure 3A), this was
not specific to mutant HTT, as was the case for HDAC4, and
HDAC5 failed to immunoprecipitate HTT from brain lysates
(Figure 3D).
To further explore this association between HDAC4 and
mutant HTT, we performed immunohistochemistry to determine
whether HDAC4 co-localized with nuclear and/or cytoplasmic
inclusions. For this purpose, we validated a number of
commercially available antibodies and found CS2072 to be
specific for HDAC4 by fluorescent immunolabelling as it gave no
signal on HDAC4KO P3 brain sections (Figure S3A). Consistent
with our western blot results, HDAC4 was localised to the
cytoplasm appearing as a punctate pattern in adult brains
(Figures 3E and S3B and S3C). This cytoplasmic localisation of
HDAC4 is supported by its co-localisation with the synaptic
markers synaptophysin and PSD95 (Figure S3C). Confocal
microscopy showed that the S830 HTT antibody detects
huntingtin aggregates in R6/2 and HdhQ150 brains and that
HDAC4 co-localised with some but not all cytoplasmic inclusions
(Figures 3E and S3B) in both cases. Taken together, our data
indicate that HDAC4 associates with soluble mutant HTT in vivo
and co-localizes with cytoplasmic inclusions in all brain regions
studied.
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Figure 2. HDAC4 knock-down delays aggregate formation in R6/2 and HdhQ150 mouse models of HD. (A) Seprion ligand ELISA was
used to quantify aggregate load in the cortex of R6/2 and Dble::R6/2 mice at 4, 9, and 15 wk of age. Values for the Dble::R6/2 mice were plotted as a
percentage of R6/2 aggregate load (n=6). (B) TR-FRET was used to determine the levels of soluble exon 1 HTT in the cortex of R6/2 and Dble::R6/2
HDAC4: A Novel Therapeutic Target for HD
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HDAC4 Reduction Does Not Rescue Global Transcription
Dysregulation
Transcriptional dysregulation is a well-documented molecular
characteristic of HD pathogenesis. A comparative study of the
striatal transcription profiles of seven mouse models and HD post
mortem brains showed that the dysregulated signature in R6/2
and HdhQ150 models was highy comparable and in both cases
more closely replicated that observed in human HD tissue than
that of the other mouse models [34]. HDAC inhibitors were
initially pursued as a therapy for HD because of their potential
for reversing these transcriptional changes. Therefore, we
performed Affymetrix microarray profiling of 9- and 15-wk
cortex for WT, Hdac4Het, R6/2, and Dble::R6/2 mice to assess
whether HDAC4 knock-down might rescue the global transcrip-
tional dysregulation that occurs in R6/2 mice. As expected the
cortical expression profile was profoundly changed between WT
and R6/2 mice by 9 wk of age and was further dysregulated at
15 wk (Figure 4A). However, comparison of the R6/2 and
Dble::R6/2 profiles indicated that only a very small number of
probe sets were predicted to be differentially expressed at
statistically significant levels (Figure 4A). This suggested that
reduction in HDAC4 had not served to rescue transcriptional
dyregulation. We used Taqman qPCR to validate the predicted
changes in gene expression between R6/2 and Dble::R6/2
cortex. We were only able to detect statistically different
expression levels of small effect size for Secis and Casc4, and in
both cases this was in the opposite direction of that predicted by
the arrays (Figure 4B).
Dysregulation of Bdnf promoter transcripts is a well-charac-
terised hallmark of disease progression in HD [35], and restoration
of Bdnf levels has been shown to correlate with phenotypic
improvements in HD mouse models. As Bdnf probe sets were not
represented on the arrays, we used Taqman qPCR to measure the
levels of multiple Bdnf promoter trancripts as well as the coding
exon (Bdnf-b) in cortex at 15 wk of age. We found that HDAC4
reduction increased Bdnf-b levels in WT cortex and almost restored
the R6/2 dysregulated Bdnf transcripts to WT levels in Dble::R6/2
mice (Figure 4C).
HDAC4 Knock-Down Improves MSN Membrane
Properties and Cortico-Striatal Synaptic Function
MSNs in symptomatic R6/2 mice show pronounced morpho-
logical abnormalities, including dendritic shrinkage and spine loss.
Largely consistent with these anatomical changes, at a behavior-
ally symptomatic age, R6/2 MSNs display a marked increase in
membrane resistance, depolarization of the resting membrane
potential (RMP), and an increased intrinsic excitability in response
to current injection [36]. These phenotypes indicate that the R6/2
MSNs are hyperexcitable relative to MSNs in WT animals. In
addition, symptomatic R6/2 mice display a progressive impair-
ment in corticostriatal connectivity [37]. In combination, this
reduction of cortical input, coupled with the abnormal excitability
of the MSNs within the R6/2 striatum, will have serious
consequences for appropriate striatal information processing and
resultant basal ganglia output. These features likely contribute and
in part underlie the impaired behavioral function exhibited by
these mice. We determined the extent of functional improvement
in MSNs from Dble::R6/2 as compared to R6/2 mice at 7–8 and
12 wk of age. As previously published, R6/2 MSNs exhibited a
higher membrane resistance than those from WT and Hdac4HET
mice at both ages, which was restored to WT levels in Dble::R6/2
mice (Figure 5A,E).
While R6/2 MSNs at 7–8 wk of age were not significantly
depolarized (Figure 5B), by 12 wk the RMP was depolarized by
approximately 3 mV relative to WT MSNs, and this was rescued
in the Dble::R6/2 mice (Figure 5F). Despite previous reports of
reduced rheobasic current (minimum current injection required to
elicit an action potential) in R6/2 mice [36], this was a modest
phenomenon in our hands and the reduction of HDAC4 in the
Dble::R6/2 mice had no effect (Figure 5C,G). Action potential
amplitude was, however, significantly reduced in R6/2 compared
to WT and Hdac4HET at both ages and was fully restored in the
Dble::R6/2 mice (Figure 5D,H). To assess an improvement in
corticostriatal transmission, glutamatergic excitatory postsynaptic
currents (EPSCs) were evoked by stimulating layer V cortical
afferents innervating the striatum. In both 7–8 and 12 wk age
groups, R6/2 mice showed significant reduction in EPSC
amplitude for any given stimulus intensity applied. There was no
difference in evoked EPSCs per genotype between the two age
groups, and the data were therefore pooled (n=28–32 neurons per
genotype; Figure 5I). In the Dble::R6/2 mice, a significant
restoration of evoked EPSC amplitude compared to R6/2 was
noted. To further delineate the locus of this improvement, a
paired-pulse stimulation paradigm (20 ms interstimulus interval)
was employed to specifically assess glutamate release probability.
R6/2 corticostriatal synapses displayed higher paired-pulse ratios
than WT synapses, and this was significant in the 12-wk dataset,
indicative of impaired glutamate release in this age group. This
was fully restored in the Dble::R6/2 mice (Figure 5J). In
agreement with the reduction in evoked glutamate release in
R6/2 corticostriatal synapses, quantal glutamate release within the
striatum, which can arise from release at both thalamostriatal and
corticostriatal presynaptic terminals, was severely depressed in the
7–8-wk-old mice [mean frequency of mEPSCs in MSNs from
WT=2.360.25 Hz (n=12), Hdac4HET=1.8760.38 Hz (n=11),
R6/2 mice= 0.1360.03 Hz (n=11)]. The Dble::R6/2 mice
showed a profound rescue in this phenotype, with a mean
frequency of mEPSCs of 1.160.14 Hz (n=12) (significance
against R6/2 frequency assessed by Kolmogirov–Smirnoff analysis
p,0.0001; Figure 5K,L). There was no change in the amplitude of
mEPSCs in R6/2 compared to WT mice, suggesting that
postsynaptic 2-amino-3-(5-methyl-3-oxo-1,2-oxazole-4-yl) propa-
noic acid (AMPA) receptor function was not impaired in the HD
model, and did not contribute to the impairment in glutamatergic
mice at 4, 9, and 15 wk of age (n= 6). (C) Seprion ligand ELISA was used to quantify aggregate load in the striatum, cortex, and cerebellum of
HdhQ150 and Dble::HdhQ150 mice at 6 and 10 mo of age. Values for the Dble::HdhQ150 mice were plotted as a percentage of aggregate load of
HdhQ150 mice (n$7). (D) Representative S830 immunoblot of cortical lysates showing the difference in soluble and aggregated exon 1 HTT between
R6/2 and Dble::R6/2 (Dble) mice and how this change occurs with age. (E) Comparison of HDAC4 levels in the nuclear and cytoplasmic fractions of R6/
2 and Dble::R6/2 (Dble) brains by western blot. The purity of the fractions is shown in Figure S2D. (F) Western blot of detergent-insoluble high
molecular weight (HMW) aggregates isolated from the nuclear and cytoplasmic fractions of R6/2 and Dble::R6/2 (Dble) brains, resolved by agarose gel
electrophoresis (AGERA), and immunodetected with the S830 antibody (representative of three experiments) (n= 8). The purity of the fractions is
shown by western blotting with a-tubulin and histone H3. (G) Western blot of HDAC4 in the cytoplasmic fraction of R6/2 and Dble::R6/2 (Dble) brains
at 9 wk of age. HDAC4 levels were measured by densitometry and calculated relative to a-tubulin. Error bars are SEM. p values were calculated using
Student’s t test.
doi:10.1371/journal.pbio.1001717.g002
HDAC4: A Novel Therapeutic Target for HD
PLOS Biology | www.plosbiology.org 6 November 2013 | Volume 11 | Issue 11 | e1001717
HDAC4: A Novel Therapeutic Target for HD
PLOS Biology | www.plosbiology.org 7 November 2013 | Volume 11 | Issue 11 | e1001717
transmission. mEPSC amplitude was unchanged in the Hdac4HET
or Dble:R6/2 animals relative to WT or R6/2 mice (Figure 5M).
In conclusion, the combined restoration of the membrane
properties of MSNs from the Dble:R6/2 mice alongside the
improvement in glutamatergic cortical input to the striatum would
be expected to significantly improve striatal information process-
ing, normalize aberrant basal ganglia output, and result in an
improvement in behavioral function.
HDAC4 Knock-Down Improves Neurological Phenotypes
in R6/2 Mice
In order to evaluate whether the molecular and electrophysi-
ological changes that had been detected in the Dble::R6/2 mice
might ameliorate HD-related behavioural and physiological
phenotypes, we employed a set of quantitative, well-characterised
tests. Mice were well matched for CAG repeat length (Table S1),
and phenotypic parameters were measured from 4 to 15 wk of age
in WT, Hdac4HET, R6/2, and Dble::R6/2 mice. All analyses
were performed blind to genotype, and in all cases, the progression
of R6/2 phenotypes was consistent with previous reports.
Rotarod performance is a sensitive indicator of balance and
motor coordination that has been reliably shown to decline in R6/
2 mice. In line with previous results, R6/2 rotarod performance
was impaired by 8 wk (p,0.001) and deteriorated further with age
(Figure 6A). HDAC4 knock-down had no impact on the
performance of WT mice. However, it significantly improved
R6/2 rotarod performance at all ages and delayed the progression
of rotarod impairment by 1 mo to the extent that 12-wk-old
Dble::R6/2 mice performed as well as 8-wk-old R6/2 mice
(Figure 6A).
At 14 wk of age, close to end stage disease, the deterioration in
the appearance of the Dble::R6/2 mice was considerably less
marked than that of R6/2. To document this, we performed a
modified SHIRPA analysis [38] and measured 16 phenotypic
parameters (Table S2), for which nine gave a positive score in R6/
2 as compared to WT mice. In all cases, the appearance of these
phenotyes was improved in the Dble::R6/2 mice when compared
to R6/2 (Figure 6B). In particular, piloerection and tremor could
not be detected in Dble::R6/2 mice, and hunched back and body
tone were vastly improved (Figure 6B). The phenotypic improve-
ments are evident in Videos S1 and S2, and in the light of these, it
was surprising that we were unabe to detect an any marked
decrease in body weight loss (Figure 6D). The dramatic
improvement in the appearance of the mice led us to assess
whether HDAC4 knock-down had pro-survival effects, and we
found that it extended the lifespan of R6/2 mice by approximately
20%, p=0.0004 (log-rank test) (Figure 6C).
Brain weight was measured for cohorts of mice that were culled
at 8, 12, and 15 wk of age, and as previously described, there was a
progressive decrease in the weight of R6/2 brains as compared to
WT. HDAC4 knock-down resulted in a very slight but statistically
significant increase in brain weight at 9 and 12 but not at 15 wk of
age (Figure 6E).
Discussion
There is mounting support for the use of HDAC inhibitors in
the treatment of a wide range of brain disorders, predominantly
aimed at pathological alterations in the brain transcriptome.
HDAC4 is a transcriptional repressor that is normally retained in
the cytoplasm, but localises to the nucleus upon de-phosphoryla-
tion [39,40]. In line with previous reports [41], we found that
HDAC4 was located in the cytoplasm in mouse brain and showed
that it did not relocate to the nucleus during disease progression.
We demonstrated that HDAC4 associates with mutant HTT in a
polyQ-dependent manner in vivo, consistent with an association
that occurs between the polyQ stretch in HTT and the Q-rich
domain of HDAC4. In line with these observations, we found that
HDAC4 co-localised with cytoplasmic inclusions in both R6/2
and knock-in HD mouse models. The genetic knock-down of
HDAC4 led to a significant delay in the cytoplasmic aggregation
process and led to a significant restoration of synaptic function. At
a physiological level, knock-down of HDAC4 extended lifespan
and partially restored motor coordination and other neurological
phenotypes. This suggests that a cytoplasm-based pathophysio-
logical mechanism contributes to key aspects of neurodegenerative
phenotype observed in HD.
A cytoplasmic mechanism of action for HDAC4-mediated
beneficial effects was unexpected. In general, HDACs have been
pursued as therapeutic targets because of their impact on
epigenetics and transcription. HDAC4 is known to repress
MEF2 in muscle [40], and it has been proposed that HDAC4
binds to HDAC3 to activate its deacetylase domain [24].
However, we found no impact on global transcriptional dysreg-
ulation upon HDAC4 knock-down in R6/2 mice, consistent with
a predominantly cytoplasmic localisation of HDAC4. Surprisingly,
the absence of HDAC4 in knock-out postnatal brain tissue had
little effect on the brain transcriptome [42]. In fact, it has been
shown that HDAC4 does not function as a lysine-deacetylase [43],
and consistent with this, we found that HDAC4 knock-out had no
effect on global acetylation in brain in vivo [42]. Our demonstration
that the dysregulation of Bdnf promoter transcripts was alleviated
in the double mutant mice is consistent with a cytoplasmic-based
mechanism of action. Bdnf expression is repressed by RE1
silencing transcription factor (REST), which is retained in the
cytoplasm in a complex containing HTT and which translocates to
the nucleus in response to HD pathology [44]. The cytoplasmic
aggregation process initiates prior to a reduction in Bdnf transcripts
in R6/2 and other HD mouse models, and therefore it is not
surprising that a delay in this cytoplasmic pathology might in turn
result in a delay in Bdnf dysregulation.
Our demonstration that a delay in the cytoplasmic aggregation
process has beneficial consequences is supported by the published
correlation between the appearance of neuropil aggregates and
disease progression [45] and is consistent with previous predictions
[46]. In the human HD post mortem brain, neuropil aggregates are
much more common than nuclear inclusions, present in a large
Figure 3. HDAC4 interacts with mutant huntingtin in vitro and in vivo and colocalizes with cytoplasmic inclusions. (A) GST pull-down
assays revealed that HDAC4 interacts with mutant (53Q) but not WT (20Q) exon 1 HTT. In contrast HDAC5 weakly interacts with both mutant and WT
exon 1 HTT. The coomassie stained gel shows the exon 1 HTT GST fusion proteins that were used to pull-down 35S-methioine labelled recombinant
HDAC4 or HDAC5. (B) Western blot probed for HTT (MAB2166 or MW1) after immunoprecipitation with HDAC4 (DM-15) from brain tissue from 8-wk-
old WT and HdhQ150 heterozygous and homozygous mice (representative picture of three independent experiments). (C) Western blot probed for
mutant HTT (MW1) after immunoprecipitation with HDAC4 (H-92) from brain tissue from 8-wk-old WT, HdhQ20, and HdhQ80 homozygous mice. (D)
Western blot probed for mutant HTT (MAB2166 or MW1) after immunoprecipitation with HDAC5 (ab56929) from brain tissue from 8-wk-old WT and
HdhQ80 homozygous mice. (E) Representative immunofluorescence images of cortex from 14-wk-old R6/2 and 23-mo-old HdhQ150 mice
immunostained for mutant HTT (S830) and HDAC4 (CS2072) and counterstained with DAPI. A similar pattern of cytoplasmic co-localisation was also
seen in the striatum and hippocampus. Scale bar, 15 mm. IP, immunoprecipitation; ID, immunodetection.
doi:10.1371/journal.pbio.1001717.g003
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Figure 4. HDAC4 knock-down does not rescue global transcriptional dysregulation. (A) Affymetrix arrays were used to determine the
effect of Hdac4 knock-down on the cortical transcription profile of WT and R6/2 mice at 9 and 15 wk of age (n$8 per genotype per time point). The
number of genes that were significantly altered between genotypes with a fold-change of .30% for each pairwise comparison is noted. Statistical
significance was determined after FDR-correction at a stringency of p#0.05. (B) Taqman qPCR validation of the genes that were predicted to be
differentially expressed between R6/2 and Dble::R6/2 cortex at 9 wk of age. See Table S3 for gene abbreviation definitions. (C) Cortical Bdnf mRNA
levels for promoter transcripts 1, 2a, 4, and 5 as well as the coding exon (B) were assessed by Taqman qPCR at 15 wk of age. All Taqman qPCR values
HDAC4: A Novel Therapeutic Target for HD
PLOS Biology | www.plosbiology.org 9 November 2013 | Volume 11 | Issue 11 | e1001717
numbers, and potentially associated with onset of clinical
symptoms [47]. Our data suggest that HDAC4 might modulate
HTT aggregation through a direct interaction serving to template
or nucleate soluble HTT. Alternatively, given that HDAC4 may
self-aggregate, it could influence HTT aggregation indirectly
through perturbation of proteostasis networks [48]. The delay in
HTT aggregation afforded by a reduction in HDAC4 was most
pronounced in presymptomatic and early-stage disease and
diminished with disease progression, presumably reflecting
changes in aggregation kinetics. This association between pheno-
typic improvements and a shift from aggregated to soluble mutant
exon 1 HTT is consistent with our previously published in vivo
studies [49,50]. Our data provide no information as to the
aggregate species that is toxic, or as to whether all species of
aggregates have detrimental consequences, but only indicate that
shifting the equilibrium toward soluble HTT is beneficial in vivo.
The improvement in synaptic function as a consequence of
HDAC4 knock-down was not related to a restoration in the
expression level of dysregulated synaptic transcripts. Instead, it
may act through reducing cytoplasmic aggregation as neuropil
aggregates have been shown to inhibit axonal transport, synaptic
function, and glutamate release in HD fly models [51]. The
restoration of corticostriatal synaptic function demonstrated that
the reduction of HDAC4 has functional consequences in the brain.
However, in this study, HDAC4 was ubiquitously knocked down,
and as HD has a peripheral component to its pathophysiology
[52], it is conceivable that the reduction of HDAC4 also had
beneficial consequences in tissues other than the brain. Given that
HDAC4 has well-established functions in muscle, that muscle
atrophy is a major symptom of HD, and that HDAC4 has been
linked to disease progression in an ALS mouse model [53], we are
currently investigating the extent to which HDAC4 reduction in
muscle might contribute to the improved HD phenotypes.
The administration of HDAC inhibitors has been shown to
improve disease phenotypes in a wide range of HD models [5]. To
better understand which HDACs, when inhibited, are most
responsible for these beneficial consequences, we embarked on a
series of genetic manipulations in HD mouse models. In this article
we show that the genetic knock-down of HDAC4 delayed
cytoplasmic aggregation, improved synaptic function, and im-
proved disease phenotypes. In contrast, the genetic knock-down of
HDAC3 [27] and the class IIa members HDAC7 [10], HDAC5,
and HDAC9 (our unpublished data) had no effect on R6/2
phenotypes. Strikingly, we recently showed that administration of
SAHA caused a reduction in HDAC2 and HDAC4 at the protein
but not RNA level in some R6/2 brain regions and that this
correlated with a reduction in aggregation and a restoration of
cortical Bdnf transcripts [11]. Therefore, we speculate that the
beneficial effects of SAHA were at least in part transmitted
through the down-regulation of HDAC4 via a mechanism not
related to its enzyme activity.
Perhaps the best validated therapeutic target for HD is the HTT
protein, and the reduction of HTT through gene silencing is being
developed using both antisense oligonucleotides and RNAi [54–
56]. However, delivery to the brain is a major challenge for these
approaches, and as HTT has many essential functions, the
potential liability of decreasing HTT to a detrimental level cannot
be ignored. We have shown that reduction of HDAC4 shifts the
ratio from aggregated to soluble HTT and therefore acts directly
on the HD mutation. Our demonstration that HDAC4 levels can
be decreased through the administration of a small brain-
penetrant molecule (SAHA) is extremely promising as more
selective inhibitors (e.g., specific to HDAC4 or class IIa enzymes)
may have similar effects, making it possible to target HTT
aggregation with a small molecule. Finally, these findings may
have wider implications as HDAC4 is a component of Lewy
Bodies in Parkinson’s disease brains [57] and administration of
SAHA improved the synaptic plasticity and learning behaviour in
an Alzheimer disease model [58].
Materials and Methods
Ethics Statement
All animal work was approved by the local ethics committees
and was performed in accordance with UK Home Office
regulations or the Swiss Law (Kantonales Veterina¨ramt Basel-
Stadt).
Mouse Maintenance and Breeding, Genotyping, and CAG
Repeat Sizing
Hemizygous R6/2 mice were bred by backcrossing R6/2 males
to (CBA6C57BL/6)F1 females (B6CBAF1/OlaHsd, Harlan Olac,
Bicester, UK). Similarly, the Hdac4 knock-out colony [21] was
maintained by backcrossing heterozygous males to B6CBAF1/
OlaHsd females. HdhQ150 homozygous mice on a
(CBA6C57BL/6)F1 background were obtained by intercrossing
HdhQ150 heterozygous CBA/Ca and C57BL/6J congenic lines as
described previously [19]. The HdhQ20 and HdhQ80 mice were
from CHDI colonies at The Jackson Laboratory (Bar Harbor,
ME) and maintained on a C57BL/6/J background. 129S2/SvHsd
females were from Harlan Olac. The cross between HdhQ150 and
Hdac4HET mice, both on a C57BL/6 background, was performed
at Novartis. All animals had unlimited access to food and water,
were subject to a 12-h light/dark cycle, and housing conditions
and environmental enrichment were as previously described [59].
The R6/2 colony was kept on breeding chow (Special Diet
Services, Witham, UK).
Genomic DNA was isolated from an ear-punch. R6/2 and
HdhQ150 mice were genotyped by PCR, and the CAG repeat
length was measured as previously described [25]. PCR conditions
for genotyping Hdac4 knock-out mice were for WT band: Fw:
CTTGTTGAGAACAAACTCCTGCAGCT, Rw: AGCCCTA-
CACTAGTGTGTGTTACACA; for Hdac4 mutant band: Fw:
AGCCCTACACTAGTGTGTGTTACACA, Neo Rw: CCAT-
GGATCCTGAGACTGGGG.
Cycling conditions were 4 min at 95uC, 356 (30 s at 95uC; 45 s
at 60uC; 2 min at 72uC), 10 min at 72uC using Taq polymerase
and buffer from Promega. The HdhQ20, HdhQ80 mice [60] were
genotyped as described [61] using the Hotstart polymerase
(Thermoscientific).
Dissected tissues were snap frozen in liquid nitrogen and stored
at 280uC until further analysis.
Behavioural and Physiological Assessment
All behavioural tests were performed as previously described,
and the data were analysed by repeated measures general linear
model ANOVA with the Greenhouse Geisser post hoc test using
SPSS software [59]. Pair-wise statistical comparisons were
corrected for multiple comparisons using Bonferroni post hoc test
in SPSS. Survival was assessed blind to genotype, and mice were
were normalized to the geometric mean of three housekeeping genes: Atp5b, Canx, and Rpl13a. Error bars are S.E.M (n= 8). *p,0.05, **p,0.01,
***p,0.001; NS, not significant.
doi:10.1371/journal.pbio.1001717.g004
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euthanized when they reached end-stage disease. The data are
presented as Kaplan–Meier cumulative survival functions and
statistically analysed by the log-rank test.
RNA Extraction, Taqman Real-Time PCR, and Affymetrix
Gene Expression Arrays
Total RNA was extracted with the mini-RNA kit accordingly
to manufacturer instructions (Qiagen). Reverse transcription (RT)
was performed using MMLV superscript reverse transcriptase
(Invitrogen) and random hexamers (Operon), and all Taqman-
qPCR reactions were performed using the Chromo4 Real-Time
PCR Detector (BioRad) as described [35]. Expression level of the
gene-of-interest was normalised to the geometric mean of three
endogenous housekeeping genes (Primer Design) as described
[35]. The primer and probe sequences are detailed in Table S3.
For the Affymetrix arrays, biotinylated cRNAs were prepared
from 200 ng total RNA using the GeneChip 39 IVT Express Kit
(Affymetrix) following the manufacturer’s instructions. cRNA
(15 mg) was hybridized to GeneChip Mouse Genome 430 version
2.0 Arrays (Affymetrix) and processed, stained, and scanned
according to the manufacturer’s recommendations. The quality of
input RNAs and cRNAs was verified with the Bioanalyzer 2100
(Agilent Technologies) before use. Microarray quality control was
performed using the software package provided on RACE [62].
Chips with a median normalized unscaled standard error greater
than 1.05 were excluded. Affymetrix annotations (version 3.0)
were used for probeset-to-gene assignments. Two-tailed t test was
performed to assess the differences in gene expression between
groups for each genotype (WT n=8; R6/2 n=9; Hdac4HET n=8;
Dble n=9). Corrections for multiple testing were performed using
the false discovery rate (FDR) according to Benjamini and
Hochberg [63] with a significance threshold of p,0.05. The array
datasets can be found at NCBI GEO accession number
GSE38237.
Antibodies, Western Blotting, and Seprion ELISA
All primary and secondary antibodies used in this study are
presented in Table S4. Preparation of protein lysates and western
blotting were as described previously [11]. In general, 20 mg
protein lysate was fractionated on 10% SDS-PAGE gels.
Aggregates were captured in Seprion ligand-coated plates
(Microsens) and detected using the S830 sheep polyclonal or
MW8 mouse monoclonal antibodies as described [25].
TR-FRET
Sample preparation and the TR-FRET assay were performed
as previously described [26].
Nuclear Cytoplasmic Fractions and Agarose Gel
Electrophoresis for Resolving Aggregates (AGERA)
Nuclear and cytoplasmic fractions were prepared as previously
described [64], and their purity was determined by immunoblot-
ting with antibodies to anti-histone H3 and a-tubulin. The
AGERA assay was performed as described [65]. In general 100 mg
of nuclear or cytoplasmic fractions, isolated from whole snap
frozen brains, were loaded in nonreducing Laemmli buffer onto
1.5% agarose gels supplemented with 0.1% SDS and run at 3 V/
cm followed by western blotting and immunodetection with anti-
HTT (S830) antibodies. The high molecular weight protein
marker was from Invitrogen.
Co-Immunoprecipitation
Co-immunoprecipitation was performed as previously described
[66]. Briefly, protein lysates were prepared from whole brains in
HEPES buffer and incubated with protein-G Dynabeads (Invitro-
gen) overnight at 4uC on a rotating platform.
Plasmids and GST Pull-Downs
The full-length mouse Hdac4 gene in pCMV6 was obtained
from Origene. This was amplified by PCR using high fidelity
polymerase (Roche) and subsequently cloned into pCR2-Topo
(Invitrogen) accordingly to the manufacturer’s instructions. The
detailed protocol used for GST pull-downs is available in the Text
S1.
Immunohistochemistry and Confocal Microscopy
For immunohistochemical studies, brains were frozen in
isopentane at 250uC and stored at 280uC until further analysis.
We cut 10–15 mm sections using a cryostat (Bright instruments),
air dried and immersed them in 4% PFA in PBS for 15 min, and
washed them for 365 min in 0.1% PBS-Triton X-100. Blocking
was achieved by incubation with 5% BSA-C (Aurion) in 0.1%
PBS-Triton X-100 for at least 30 min at RT. Immunolabelling
with primary antibodies in 0.1% PBS-Triton X-100, 1% BSA-C
(HDAC4, S830) was completed by overnight incubation in a
humidity box at 4uC. Sections were washed 36 in PBS,
incubated for 60 min at RT in a dark box with the appropriate
combinations of secondary antibodies diluted in PBS, washed 36
in PBS, and counterstained with DAPI (Invitrogen). Sections
were mounted in Vectashield mounting medium (Vector
Laboratories). Sections were examined using the Leica TCS
SP4 laser scanning confocal microscope and analysed with Leica
Application Suite (LAS) v5 (Leica Microsystems, Heidelberg,
Germany).
Electrophysiological Recordings
Detailed procedures for acute striatal slice preparation, patch-
clamp recordings, and the isolation of miniature excitatory
postsynaptic currents (mEPSCs), along with the appropriate
statistical analysis, can be found in Text S1.
Statistical Analysis
All data were analysed with Microsoft Office Excel and two-
tailed Student’s t test or as otherwise stated.
Figure 5. HDAC4 reduction improves the electrophysiological characteristics of MSNs and corticostriatal synaptic function. (A–H)
Box and whisker plots of (A, E) input resistance (Rm), (B, F) RMP, (C, G) rheobase current, and (D, H) spike amplitude from corticostriatal slices at (A–D)
7–8 and (E–H) 12 wk of age. Box and whisker plots: +, mean; box, interquartile range; whisker, 10–90 percentile; outliers, closed circles. (I)
Measurement of evoked EPSCs following cortical stimulation showed that the R6/2 mice show lower basal transmission compared to WT or
Hdac4HET and that this is restored in the Dble::R6/2 mice at 7–12 wk of age. (J) R6/2 MSNs have a higher paired-pulse ratio than WT (interstimulus
interval, 20 ms), indicating reduced glutamate release probability. This is fully restored in Dble::R6/2 mice at 12 wk of age. (K) Representative traces of
miniature EPSCs (mEPSCs) at 8 wk. R6/2 mice show strongly depressed mEPSC frequency, which is significantly rescued in the Dble::R6/2 mice. (L, M)
Average cumulative plot of mEPSC interevent interval (0.1 s bins) (L) or amplitude (1 pA bins) (M); n= 11–12 for all four genotypes. Statistical analysis
was performed by (A–H and J) one-way ANOVA with Tukey’s multiple comparison test, (I) two-way ANOVA with Bonferroni multiple comparison test,
and (L, M) Kolmogorov–Smirnov (KS) test. *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pbio.1001717.g005
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Figure 6. HDAC4 knock-down improves neurological phenotypes and extends survival. (A) Reduction in HDAC4 results in a pronounced
delay in impaired motor coordination as determined by rotarod performance (n$13/genotype). (B) Assessment of neurological phenotypes via a
modified SHIRPA protocol (see Table S2 for details). Of the nine parameters that distinguished R6/2 and WT mice, all were improved in the Dble::R6/2
mice. See also Video S1 and Video S2. (C) Kaplan–Meier analysis showed that knock-down of HDAC4 significantly increased R6/2 survival (n$13/
genotype). (D) Reduction of HDAC4 did not result in an overall improvement in the failure of R6/2 mice to gain weight, although Dble::R6/2 mice
were significantly heavier than R6/2 mice at 15 wk of age (n$13/genotype). (E) There was a slight but statistically significant increase in the brain
weight of Dble::R6/2 as compared to R6/2 mice at 4 and 9 wk of age (n$10/genotype). Statistical analysis was performed by GLM-ANOVA with
Greenhouse Geisser post hoc analysis (B and D), by multiple comparisons using Bonferroni post hoc test (B and D), and by log-rank test (C).
doi:10.1371/journal.pbio.1001717.g006
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Supporting Information
Figure S1 HDAC4 reduction does not alter the expres-
sion levels of HTT exon 1, endogenous Htt, or other
Hdacs. (A) Taqman qPCR showed no difference in HTT exon 1
transgene levels in the cerebellum or in the striatum of R6/2 and
Dble::R6/2. (B) There was no difference in endogenous Htt levels
in the cerebellum or in the striatum of WT, Hdac4HET, R6/2,
and Dble::R6/2 mice as determined by Taqman qPCR. (C)
Taqman qPCR showed that the cerebellar transcript level of
Hdac4 was decreased in Hdac4HET and Dble::R6/2 mice, but that
the expression level of other Hdacs did not differ from WT in the
cerebellum of Hdac4HET, R6/2, and Dble::R6/2. (D) Taqman
qPCR showed that the striatal transcript level of Hdac4 was
decreased in Hdac4HET and Dble mice, but that the expression
level of other Hdacs did not differ from WT in the striatum of
Hdac4HET, R6/2, and Dble::R6/2. Taqman qPCR values were
normalized to the geometric mean of three housekeeping genes:
Atp5b, Canx, and Eif4a (for cerebellum) and Atp5b, Yhwaz, and Ubc
(for striatum). Error bars are SEM. p values were calculated using
Student’s t test (n=8). **p,0.01, ***p,0.001.
(TIF)
Figure S2 HDAC4 knock-down delays aggregate forma-
tion in multiple CNS tissues. (A) Seprion ligand ELISA was
used to quantify the aggregate load in the brain stem,
hippocampus, cerebellum, and striatum of R6/2 and Dble::R6/
2 mice at 4, 9, and 15 wk of age. R6/2::Dble values were plotted
as a percentage of R6/2 aggregate load (n=6). (B) TR-FRET was
used to determine the levels of soluble exon 1 HTT in the brain
stem, hippocampus, and cerebellum of R6/2 and Dble mice at 4,
9, and 15 wk of age (n=6). (C) Western blot demonstrating that
the H92 antibody detects HDAC4 as the signal is absent from
HDAC4 knock-out tissue. Immunoprecipitation with the HDAC4
antibodies H92, DM-15, and CS2072 demonstrates that they are
all capable of immunoprecipitating HDAC4 as detected with H92.
ID, immunodetection. (D) Western blot of detergent-insoluble
high molecular weight aggregates isolated from the nuclear and
cytoplasmic fractions of R6/2 and Dble::R6/2 (Dble) brains at
4 wk of age, resolved by agarose gel electrophoresis (AGERA), and
immunodetected with the S830 antibody (n=8). The purity of the
fractions was demonstrated by western blotting with a-tubulin and
histone H3. (E) Western blot of HDAC4 protein levels in the
cytoplasmic fractions of R6/2 and Dble::R6/2 (Dble) brains at
4 wk of age. HDAC4 levels in the cytoplasmic fractions were
measured by densitometry and calculated relative to a-tubulin. (F)
Seprion ligand ELISA was used to quantify aggregate load in the
cortex of R6/2-129S mice as compared to R6/2-CBF mice at
9 wk of age. R6/2-129S values were plotted as a percentage of
aggregate load in R6/2-CBF mice (n=7). R6/2-129S mice have
the same Hdac4 haplotype as Dble mice but with a functional
Hdac4 gene. Error bars are SEM. p values were calculated using
Student’s t test.
(TIF)
Figure S3 HDAC4 associates with exon 1 HTT and co-
localizes with cytoplasmic inclusions and with synaptic
markers. (A) Validation of the specificity of the HDAC4
antibodies used for immunohistochemistry. Representative immu-
nofluorescent images of cortex from WT (A) and Hdac4KO (B)
mice stained for HDAC4 at P3 and counterstained with DAPI.
Scale bar, 10 mm. (B) Representative immunofluorescent images of
the striatum from 14-wk-old WT and R6/2 mice immunostained
for mutant HTT (S830) and HDAC4 (CS2072), and counter-
stained with DAPI. Scale bar, 15 mm. (C) Representative confocal
images of the cortex from 14-wk WT mice. Sections were stained
for synaptophysin and HDAC4 or for PSD95 and HDAC4 and
counterstained with DAPI. There was a considerable degree of co-
localisation between HDAC4 and the synaptic markers. Scale bar,
10 mm.
(TIF)
Table S1 Summary of the number of mice per genotype
used in all studies and their CAG repeat sizes. SD,
standard deviation.
(DOCX)
Table S2 Summary of neurological and physiological
phenotypes as assessed by the SHIRPA protocol.
(DOCX)
Table S3 Summary of the Taq-man assays used in this
study.
(DOCX)
Table S4 Summary of the antibodies used in this study.
WB, western blotting; IP, immunoprecipitation; IHC, immuno-
histochemistry; SEPRION, seprion ligand ELISA for aggregated
huntingtin; TR-FRET, time resolved Fo¨rster resonance energy
transfer for soluble huntingtin.
(DOCX)
Text S1 Supporting materials and methods. Plasmids and
GST pull-downs and electrophysiological recordings.
(DOCX)
Video S1 Comparison of the gait of an R6/2 mouse
(agouti) and his Dble::R6/2 littermate (black) at 14 wk
of age (males).
(MP4)
Video S2 Comparison of the appearance of an R6/2
mouse (agouti) and his Dble::R6/2 littermate (black) at
14 wk of age (males). Note improvements in body tone,
hunched back, piloerection, and general appearance.
(M4V)
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